Can an arthritis drug make melanoma immunotherapy safer?
NCT ID NCT05034536
First seen Jan 09, 2026 · Last updated May 19, 2026 · Updated 16 times
Summary
This study tests whether adding infliximab (a drug used for arthritis) to standard immunotherapy can reduce serious side effects while still treating advanced melanoma. About 36 adults with stage 3 or 4 melanoma who haven't had prior treatment will receive either immunotherapy alone or with infliximab. The goal is to see if the combination is safer and still effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.